Clinical Trial: Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06927297) titled 'Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors' on April 04.

Brief Summary: This study is a dose-escalation, prospective clinical trial to assess the safety, tolerability, and preliminary therapeutic efficacy of engineered mitochondria expressing specific tumor antigen in patients with advanced solid tumors.

Study Start Date: April 04

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor Malignancies Advanced Solid Malignancies

Intervention: BIOLOGICAL: Engineered mitochondria vaccine

Participants were assigned to receive subcutaneous injections of...